32 research outputs found
Utilization of whole genome sequencing for resolution of discrepant <i>Mycobacterium tuberculosis</i> drug susceptibility results: A case report.
Clinical Whole Genome Sequencing for Clarithromycin and Amikacin Resistance Prediction and Subspecies Identification of Mycobacterium abscessus.
S100A12 Is Part of the Antimicrobial Network against Mycobacterium leprae in Human Macrophages
Innate and Adaptive Immune Host Defense Responses Against Mycobacteria Infection in Humans
The host immune system is required for protection against disease caused by intracellular pathogens, such as mycobacteria. Activated host cells induce a variety of defense mechanisms that coordinate in order to eliminate mycobacteria. Stimulation of toll-like receptors (TLRs) as part of the innate immune system, and T-cell release of IFN-γ as part of the adaptive immune response are both associated with protection against mycobacterial disease progression. However, the various host defense pathways mediated by these two signals in human macrophages still need to be defined. Ligation of TLR2/1 with mycobacteria derived lipoproteins has been shown to trigger anti-mycobacterial activity, with the induction of antimicrobial peptides via a vitamin D-dependent pathway. Here, IFN-γ activation of human macrophages was shown to also induce killing of mycobacteria via a vitamin D-dependent antimicrobial pathway. In addition, IL-32, an IFN-γ inducible protein, was shown to mediate antimicrobial activity against mycobacteria by also inducing the vitamin D pathway.Since activation via TLR2/1 and IFN-γ converge on at least one common antimicrobial pathway, we further studied the TLR2/1 and IFN-γ inducible gene network by RNA sequencing. Bioinformatics analysis identified “defense response” as a common TLR2/1 and IFN-γ gene ontology term. A subset of genes with previously reported direct or indirect antimicrobial activity was also identified in the common dataset. The role of S100A12, a TLR2/1 and IFN-γ common gene, was further investigated in the context of leprosy, a disease caused by Mycobacterium leprae, in which the clinical manifestations correlate with immune response. S100A12 was more highly expressed in tuberculoid leprosy (T-lep), which is associated with resistance to infection, compared to lepromatous leprosy (L-lep), which is associated with susceptibility to infection. S100A12 was sufficient to kill mycobacteria and was required for the TLR2/1 and IFN-γ inducible antimicrobial activity against M. leprae in human macrophages. Our data further define mechanisms for TLR2/1 and IFN-γ mediated antimicrobial response against mycobacteria
Deceiving Phenotypic Susceptibility Results on a <i>Klebsiella pneumoniae</i> Blood Isolate Carrying Plasmid-Mediated AmpC Gene <i>bla</i> <sub>DHA-1</sub>.
Recommended from our members
Deceiving Phenotypic Susceptibility Results on a Klebsiella pneumoniae Blood Isolate Carrying Plasmid-Mediated AmpC Gene bla DHA-1.
Carbapenem-resistant Klebsiella pneumoniae (CRKP) frequently causes hospital-acquired infections and is associated with high morbidity and mortality. CRKP can have multiple resistance mechanisms and only a few can be routinely detected by commercial molecular or phenotypic assays making surveillance for CRKP particularly challenging. In this report, we identified and characterized an unusual non-carbapenemase-producing CRKP carrying a rare plasmid-borne inducible AmpC gene, blaDHA-1 . The isolate was recovered from blood culture of a 67-year-old female presenting with sepsis post bladder surgery and ureteral stent removal. The primary isolate displayed an indeterminate susceptibility pattern for ceftriaxone by broth microdilution, but was susceptible by disk diffusion with one colony growing within the zone of inhibition. The ceftriaxone resistant colony was sub-cultured and had a minimum inhibitory concentration (MIC) of 2 ug/ml for imipenem (intermediate) and a zone size of 18 mm for ertapenem (resistant), but remained susceptible to cefepime and meropenem. Further phenotypic characterization of this sub-cultured isolate showed carbapenemase activity. Whole genome sequencing (WGS) revealed the presence of two subpopulations of a K. pneumoniae (MLST sequence type 11) from the primary blood culture isolate: one pan-susceptible to beta-lactams tested and the other resistant to the 3rd generation cephalosporins and ertapenem. WGS analysis identified the resistant K. pneumoniae harboring IncFIB(K) and IncR plasmids and the presence of plasmid-borne beta-lactam resistance genes bla OXA-1 and bla DHA-1, an inducible AmpC gene. Additional resistance genes against quinolones (aac(6')-Ib-cr, oqxA, oqB), aminoglycoside (aph(3')-Ia), sulfonamide (sul1), and tetracycline (tet(A)) were also identified. DHA-1 positive K. pneumoniae have been previously identified outside the US, particularly in Asia and Europe, but limited cases have been reported in the United States and may be underrecognized. Our study highlights the importance of using both extended phenotypic testing and WGS to identify emerging resistance mechanisms in clinical Enterobacterales isolates with unusual antimicrobial resistance patterns
Recommended from our members
Clinical Whole Genome Sequencing for Clarithromycin and Amikacin Resistance Prediction and Subspecies Identification of Mycobacterium abscessus.
Mycobacterium abscessus infections are an emerging health care concern in patients with chronic pulmonary diseases, leading to high morbidity and mortality. One major challenge is resistance to clarithromycin, a cornerstone antibiotic with high efficacy. Therefore, treatment is primarily guided by phenotypic susceptibility results of clarithromycin, which requires extended incubation to assess for inducible resistance. Resistance mechanisms for clarithromycin include induction of erm(41) and mutations in the 23S rRNA gene (rrl). In addition, mutations in the 16S rRNA encoding gene (rrs) can confer high-level amikacin resistance, another essential drug in the treatment of M. abscessus infections. Herein, we developed a clinical whole genome sequencing (WGS) assay for clarithromycin resistance based on rrl and erm(41) gene sequences and amikacin resistance based on the rrs sequence in M. abscessus, as well as subspecies identification. Genotypic-based predictions were determined for 104 isolates from 68 patients. The overall accuracy of genotypic prediction for clarithromycin compared with phenotypic susceptibility results was 100% (95% CI, 96.45%-100%). For amikacin, we also obtained 100% accuracy (95% CI, 96.52%-100%). The high concordance between the genotypic and phenotypic results demonstrates that a WGS-based assay can be used in a clinical laboratory for determining resistance to clarithromycin and amikacin in M. abscessus isolates. WGS can also provide subspecies identification and high-definition phylogenetic information for more accurate M. abscessus strain typing
Suppression of Poxvirus Replication by Resveratrol
Poxviruses continue to cause serious diseases even after eradication of the historically deadly infectious human disease, smallpox. Poxviruses are currently being developed as vaccine vectors and cancer therapeutic agents. Resveratrol is a natural polyphenol stilbenoid found in plants that has been shown to inhibit or enhance replication of a number of viruses, but the effect of resveratrol on poxvirus replication is unknown. In the present study, we found that resveratrol dramatically suppressed the replication of vaccinia virus (VACV), the prototypic member of poxviruses, in various cell types. Resveratrol also significantly reduced the replication of monkeypox virus, a zoonotic virus that is endemic in Western and Central Africa and causes human mortality. The inhibitory effect of resveratrol on poxviruses is independent of VACV N1 protein, a potential resveratrol binding target. Further experiments demonstrated that resveratrol had little effect on VACV early gene expression, while it suppressed VACV DNA synthesis, and subsequently post-replicative gene expression
Recommended from our members
Utilization of whole genome sequencing for resolution of discrepant Mycobacterium tuberculosis drug susceptibility results: A case report.
A 44-year-old woman undergoing therapy for acute promyelocytic leukemia (APL) developed disseminated tuberculosis. Mycobacterium tuberculosis (TB) was isolated from the blood and sputum. Initial drug susceptibility testing (DST) of the blood isolate revealed resistance to isoniazid and ethambutol but the sputum isolate showed no resistance. Due to drug resistance concerns, the patient was treated with multiple second and third-line drugs, and suffered from drug side effects. To further investigate the DST discrepancies, whole genome sequencing (WGS) was performed on both isolates. No known resistance mutations to first line or second line drugs were identified in either isolate, which was confirmed by additional susceptibility testing performed by a different reference laboratory and the California Department of Public Health (CDPH) laboratory. Treatment was reduced to a simpler and less toxic regimen due to these investigations. WGS is shown to be a valuable tool for resolving discordant phenotypic DST results of TB isolates and has the potential to provide accurate and timely results guiding appropriate therapy in the clinical setting